Shengfang Jin, Ensem Therapeutics president and CEO

BeiGene li­cens­es CDK2 in­hibitor from En­sem in po­ten­tial $1.33B deal

BeiGene has struck a deal with En­sem Ther­a­peu­tics to li­cense an oral cy­clin-de­pen­dent ki­nase 2 (CDK2) in­hibitor in ex­change for an undis­closed up­front pay­ment and up to $1.33 bil­lion in mile­stones, the com­pa­nies an­nounced Tues­day.

En­sem will al­so get tiered roy­al­ties for hand­ing over the ex­clu­sive glob­al li­cense to the drug, which the com­pa­nies said is “In­ves­ti­ga­tion­al New Drug (IND) ap­pli­ca­tion-ready” and En­sem’s most ad­vanced can­di­date. While they didn’t name the pro­gram in the press re­lease, En­sem’s web­site iden­ti­fies the BeiGene-part­nered pro­gram as ETX-197.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.